Biopharmaceutical Company
Appears in 1 story
Imcivree launches in largest indication; monitors GLP-1 competition in obesity space
For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
